Taylor Thrash, DO
Family Medicine · Murrells Inlet, SCNPI 1871158121
Payments from drug & device makers
Across 216 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$724
- AbbVie$504
- GSK$249
- AstraZeneca$205
- Amgen$198
- Abbott$168
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,917100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $724 |
| AbbVie(2 entities) | 31 | $504 |
| GSK | 14 | $249 |
| AstraZeneca | 13 | $205 |
| Amgen | 11 | $198 |
| Abbott | 7 | $168 |
| Alkermes, Inc. | 7 | $159 |
| Lilly USA, LLC | 10 | $147 |
| Xeris Pharmaceuticals, Inc. | 8 | $145 |
| Pfizer | 8 | $134 |
| Merck | 7 | $119 |
| Sanofi-aventis U.S. LLC | 3 | $96 |
| Dexcom, Inc. | 2 | $95 |
| Corcept Therapeutics | 4 | $90 |
| Exact Sciences | 5 | $87 |
| Supernus Pharmaceuticals, Inc. | 3 | $81 |
| Bayer | 5 | $80 |
| Nevro Corp. | 3 | $60 |
| Idorsia Pharmaceuticals US Inc | 4 | $53 |
| Braeburn Inc. | 2 | $49 |
| Verity Pharmaceuticals Inc. | 2 | $47 |
| Novartis | 3 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Antares Pharma, Inc. | 2 | $37 |
| Indivior Inc. | 2 | $32 |
| Tolmar, Inc. | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 3 | $26 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Cequr Corporation | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Cvrx, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Sonex Health, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$125
How this compares
$3,932 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 97 | $143,620 |
| EliquisApixaban | 56 | $73,540 |
| OzempicSemaglutide | 71 | $70,770 |
| MounjaroTirzepatide | 49 | $51,959 |
| JanuviaSitagliptin Phosphate | 53 | $48,547 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $46,190 |
| JardianceEmpagliflozin | 41 | $41,564 |
| VraylarCariprazine Hcl | 19 | $32,180 |
| XareltoRivaroxaban | 22 | $27,238 |
| FarxigaDapagliflozin Propanediol | 23 | $21,863 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 120 | $17,009 |
| Metformin Er OsmoticMetformin Hcl | 12 | $12,286 |
| MyrbetriqMirabegron | 18 | $9,966 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 314 | $9,883 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $9,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $724 | $214,391168 claims |
| PfizerEliquis | $134 | $73,54056 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $249 | $55,08972 claims |
| Lilly USA, LLCMounjaro | $147 | $51,95949 claims |
| MerckJanuvia | $119 | $48,54753 claims |
| AbbVieVraylar | $504 | $32,18019 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $205 | $30,63538 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $9,96618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Murrells Inlet
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.